Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Endocrine and neuroendocrine tumours

4851 - Improved Time to Quality of Life Deterioration in Patients with Progressive Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE: the NETTER-1 Phase III Trial


11 Sep 2017


Endocrine and neuroendocrine tumours


Neuroendocrine Tumours


Jonathan Strosberg


Annals of Oncology (2017) 28 (suppl_5): v142-v157. 10.1093/annonc/mdx368


J. Strosberg1, E.M. Wolin2, B. Chasen3, M.H. Kulke4, D. Bushnell5, M. Caplin6, R.P. Baum7, P. Kunz8, T. Hobday9, A. Hendifar10, K. Öberg11, M. Lopera Sierra12, P. Ruszniewski13, E. Krenning14

Author affiliations

  • 1 Gi Oncology, H. Lee Moffitt Cancer Center University of South Florida, 33612 - Tampa/US
  • 2 ., Montefiore Einstein Center for Cancer Care, New York/US
  • 3 Nuclear Medicine, The University of Texas MD Anderson Cancer Center, 7 - Houston/US
  • 4 Gastrointestinal Cancer, Dana-Farber Cancer Institute, Boston/US
  • 5 Nuclear Medicine, University of Iowa, Iowa/US
  • 6 Neuroendocrine Tumour Unit, Royal Free Hospital, London/GB
  • 7 Nuclear Medicine, Zentralklinik Bad Berka GmbH, 99437 - Bad Berka/DE
  • 8 Oncology, Stanford University Medical Center, Stanford/US
  • 9 Oncology, Mayo Clinic, 55905 - Rochester/US
  • 10 Oncology, Cedars-Sinai Medical Center, 90048 - Los Angeles/US
  • 11 Endocrine Oncology, University Hospital, Uppsala University, Uppsala/SE
  • 12 Medical, Advanced Accelerator Applications, 10118 - New York/US
  • 13 Oncology, Hôpital Beaujon, 92110 - Clichy/FR
  • 14 Oncology, Erasmus Medical Center, Rotterdam/NL


Abstract 4851


Neuroendocrine tumor (NET) progression is associated with deterioration in quality of life (QoL). We assessed the impact of 177Lu-DOTATATE treatment on the time to clinically relevant change (deterioration) in health-related QoL (HRQoL). The NETTER-1 trial is an international phase III study in patients with progressive, somatostatin receptor positive midgut NET. Patients were randomized to receive treatment with 177Lu-DOTATATE versus high-dose (60 mg) Octreotide LAR (Oct). EORTC questionnaires QLQC-30 and G.I.NET-21 were assessed during the trial to determine the impact of treatment on HRQoL.


231 patients completed EORTC QLQC-30 and G.I.NET-21 questionnaires at baseline and every 12 weeks thereafter until tumor progression centrally confirmed. QoL scores were converted to a 100-point scale according to EORTC instructions and individual changes from baseline scores were assessed. Time to QoL deterioration (TTD) was defined as the time from randomization to the first QoL deterioration ≥10 points for each patient in the corresponding domain scale. This magnitude of variation was considered clinically relevant. All analyses were conducted on the ITT population.


TTD was significantly longer in the 177Lu-DOTATATE arm (N = 117) vs the control arm (N = 114) for the following domains: global health status (hazard ratio (HR) 0.406; p = 0.0006), physical functioning (HR 0.518; p = 0.0147), role functioning (HR 0.580; p = 0.0298), fatigue (HR 0.621; p = 0.0297), pain (HR 0.566; p = 0.0247), diarrhea (HR 0.473; p = 0.0107), disease related worries (HR 0.572; p = 0.0176) and body image (HR 0.425; p = 0.0058). In the other domains TTD did not reach statistical significance between the arms. Differences in median TTD were clinically significant in several domains: 28.8 months vs. 6.1 months for global health status, and 25.2 months vs. 11.5 months for physical functioning.


This analysis from the NETTER-1 Phase III study demonstrates that 177Lu-DOTATATE provides a significant quality of life benefit for patients with progressive midgut NETs compared to high-dose octreotide, in addition to the meaningful increase in progression-free survival already reported.

Clinical trial identification


Legal entity responsible for the study

NETTER-1 study group and Advanced Accelerator Applications


Advanced Accelerator Applications


M. Lopera Sierra: Advanced Accelerator Applications Chief Medical Officer E. Krenning: Stock ownership. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.